Characterizing the Research Participant Recruitment Funnel for Alzheimer's Secondary Prevention Trials: Results from A National Survey of U.S. Adults.

Emily A Largent, Joshua D Grill, Jason Karlawish, Amy Bleakley

Abstract read

In one paragraph

Article in Alzheimer's & dementia. Behavior & socioeconomics of aging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Emily A LargentDepartment of Medical Ethics and Health Policy, University of Pennsylvania, Blockley Hall, 423 Guardian Drive, Philadelphia, PA 19104.

Joshua D GrillInstitute for Memory Impairments and Neurological Disorders, University of California Irvine, 3204 Biological Sciences III, Mail Code: 4545, Irvine, CA 92697.

Jason KarlawishDepartment of Medicine, Department of Medical Ethics and Health Policy, University of Pennsylvania, Blockley Hall, 423 Guardian Drive, Philadelphia, PA 19104.

Amy BleakleyDepartment of Communication, University of Delaware, 238 Pearson Hall, Newark, DE 19716.

Funding

The Alzheimer's Disease Research Center at the University of California, IrvineP30AG066519 · NIA · UNIVERSITY OF CALIFORNIA-IRVINE · PI Joshua Grill · 2020 to 2026

$27.9M

UNDERSTANDING HOW THE STUDY PARTNER REQUIREMENT IMPACTS THE DISCOVERY AND TRANSLATION OF PRECLINICAL ALZHEIMERS DISEASEK01AG064123 · NIA · UNIVERSITY OF PENNSYLVANIA · PI LARGENT, EMILY · 2019 to 2023

$637k

NIA NIH HHS K01 AG064123NIA NIH HHS P30 AG066519

6 · The paper itself

Abstract

Introduction: The steps of participant recruitment are described as a "funnel." In AD secondary prevention trials, the funnel typically yields an unrepresentative study population. Methods: A national survey of U.S. adults aged 65 and over assessed intention to enroll in a hypothetical secondary prevention trial. Among those intending to enroll, intention to ask someone to serve as their study partner was also measured. Results: In the full sample (n=603), intention to enroll - measured on a scale of 1 (very unlikely) to 5 (very likely) - was low (M: 2.37, SD: 1.31). Among those somewhat or very likely to enroll (24%, n=168), mean intention to ask a study partner was 3.45 out of 5 (SD 1.44). There were no significant differences between Black and White respondents. Discussion: Our results suggest underrepresentation of Black older adults in secondary prevention trials is not attributable to lower intention to participate or ask a study partner.

Indexed as

Alzheimer’sdiversityparticipantpreventionrecruitmentstudy partner

Identifiers

PMID40937435

DOI10.1002/bsa3.70035

PMCPMC12422305

What Socratic holds

Textmetadata

LicenceTDM

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.